LOGIN  |  REGISTER
Astria Therapeutics

Healthcare Services Group (NASDAQ: HCSG) Stock Quote

Last Trade: US$11.39 0.03 0.26
Volume: 229,140
5-Day Change: -8.44%
YTD Change: 9.84%
Market Cap: US$835.800M

Latest News From Healthcare Services Group

Delivers QoQ and YoY Growth In Revenue, Earnings and Cash Flow Revenue of $428.1 million, in line with expectations. Net income and diluted EPS of $14.0 million and $0.19. Reported and adjusted cash flow from operations of $4.3 million and $19.0 million. Reaffirms Q4 revenue estimate of $430.0 to $440.0 million and FY 2024 cash flow forecast of $40.0 to $55.0 million. BENSALEM, Pa. / Oct 23, 2024 / Business Wire / Healthcare... Read More
BENSALEM, Pa. / Sep 09, 2024 / Business Wire / Healthcare Services Group, Inc. (NASDAQ:HCSG) today announced the appointment of Vikas Singh as EVP & Chief Financial Officer, effective September 3, 2024. He will oversee HCSG’s accounting and finance operations, and play a key role in corporate development, investor relations, and the success of its long-term growth strategy. Mr. Singh brings over two decades of diverse... Read More
Raises Second Half 2024 Revenue Estimates, Reaffirms Full-Year 2024 Cash Flow Forecast Revenue of $426.3 million, in line with expectations. Net income and diluted EPS of ($1.8) million and ($0.02); includes $0.22 impact of client restructuring charges . Reported and adjusted cash flow from operations of $16.3 million and ($2.4) million. Raises Q3 and Q4 revenue estimates to $425.0 to $435.0 million and $430.0 to $440.0... Read More
BENSALEM, Pa. / Jun 03, 2024 / Business Wire / Healthcare Services Group, Inc. (NASDAQ:HCSG) today issued the following statement in response to LaVie Care Centers’ announcement that it had filed for Chapter 11 bankruptcy protection in the Northern District of Georgia. As a result of LaVie’s filing, the Company estimates a Q2 non-cash charge of approximately $0.20 per share. The Company expects to continue providing services... Read More
Exceeds Earnings Expectations, Revenue In Line Reiterates 2024 Cash Flow Forecast & Expectation for YoY Revenue Growth Revenue of $423.4 million, in line with expectations. Net income and diluted EPS of $15.3 million and $0.21; adjusted net income (1) and adjusted diluted EPS (1) of $16.5 million and $0.22. Adjusted EBITDA (1) of $28.9 million, a 10.7% increase over Q1 2023. BENSALEM, PA / Apr 24, 2024 / Business Wire /... Read More
Exceeds Earnings and Cash Flow Expectations, Revenue In-Line Revenue of $423.8 million; adjusted revenue (1) of $425.0 million, in-line with expectations. Net income and diluted EPS of $22.6 million and $0.31; adjusted net income (1) and adjusted diluted EPS (1) of $14.6 million and $0.20. Adjusted EBITDA (1) of $26.5 million, a 14.2% increase over Q4 2022. Cash flow from operations of $49.5 million; adjusted cash flow from... Read More
Revenue of $411.4 million; adjusted revenue (1) of $424.0 million, in line with expectations. Net income and diluted EPS of ($5.5) million and ($0.07); adjusted net income (1) and adjusted diluted EPS (1) of $12.5 million and $0.17, a 13.7% and 13.3% increase, respectively, over Q3 2022. Adjusted EBITDA (1) of $23.2 million, a 10.2% increase over Q3 2022. Cash flow from operations of $2.9 million; adjusted cash flow from... Read More
Robust New Business Pipeline Sets Stage For Second Half Of Year Growth BENSALEM, Pa. / Jul 26, 2023 / Business Wire / Healthcare Services Group, Inc. (NASDAQ:HCSG) reported for the three months ended June 30, 2023 revenue of $418.9 million, GAAP net income of $8.6 million, or $0.12 per basic and diluted common share, and adjusted EBITDA of $26.3 million. Q2 Results Revenue for the quarter was reported at $418.9 million, with... Read More
Continues Positive Business Momentum, Adjusted EBITDA up 18% BENSALEM, Pa. / Apr 26, 2023 / Business Wire / Healthcare Services Group, Inc. (NASDAQ:HCSG) (the “Company”) reported for the three months ended March 31, 2023 revenue of $417.2 million, GAAP net income of $12.7 million, or $0.17 per basic and diluted common share, and adjusted EBITDA of $27.5 million. Q1 Results Revenue for the quarter was reported at $417.2... Read More
Amneal Pharmaceuticals

COPYRIGHT ©2023 HEALTH STOCKS HUB